GB201914516D0 - Treatment of eye disease - Google Patents
Treatment of eye diseaseInfo
- Publication number
- GB201914516D0 GB201914516D0 GB201914516A GB201914516A GB201914516D0 GB 201914516 D0 GB201914516 D0 GB 201914516D0 GB 201914516 A GB201914516 A GB 201914516A GB 201914516 A GB201914516 A GB 201914516A GB 201914516 D0 GB201914516 D0 GB 201914516D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- eye disease
- eye
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1738—Calcium binding proteins, e.g. calmodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201914516A GB201914516D0 (en) | 2019-10-08 | 2019-10-08 | Treatment of eye disease |
US17/767,232 US20220370554A1 (en) | 2019-10-08 | 2020-10-07 | Calreticulin for Treating or Preventing an Angiogenic Eye Disease |
EP20789562.4A EP4041280A1 (en) | 2019-10-08 | 2020-10-07 | Calreticulin for treating or preventing an angiogenic eye disease |
KR1020227015264A KR20220079917A (en) | 2019-10-08 | 2020-10-07 | Calreticulin for the treatment or prevention of angiogenic eye disease |
JP2022521196A JP2023500033A (en) | 2019-10-08 | 2020-10-07 | Calreticulin for treating or preventing angiogenic eye disease |
PCT/EP2020/078173 WO2021069523A1 (en) | 2019-10-08 | 2020-10-07 | Calreticulin for treating or preventing an angiogenic eye disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201914516A GB201914516D0 (en) | 2019-10-08 | 2019-10-08 | Treatment of eye disease |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201914516D0 true GB201914516D0 (en) | 2019-11-20 |
Family
ID=68541456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB201914516A Ceased GB201914516D0 (en) | 2019-10-08 | 2019-10-08 | Treatment of eye disease |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220370554A1 (en) |
EP (1) | EP4041280A1 (en) |
JP (1) | JP2023500033A (en) |
KR (1) | KR20220079917A (en) |
GB (1) | GB201914516D0 (en) |
WO (1) | WO2021069523A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114699506A (en) * | 2021-12-30 | 2022-07-05 | 北京百华百汇生物科技有限公司 | Use of recombinant calreticulin for growing hair, protecting hair or preventing alopecia and related products |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000020577A1 (en) | 1998-10-06 | 2000-04-13 | The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Huuman Services, The National Institutes Of Health | Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth |
US6867180B1 (en) | 1998-10-06 | 2005-03-15 | The United States Of America As Represented By The Department Of Health And Human Services | Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth |
US9254310B2 (en) * | 2010-06-17 | 2016-02-09 | New York University | Therapeutic and cosmetic uses and applications of calreticulin |
TWI445543B (en) | 2012-05-03 | 2014-07-21 | Univ Nat Sun Yat Sen | Medication for treating choroidal neovascularization |
CN104704126B (en) | 2012-07-12 | 2018-03-20 | Uab巴尔特玛斯公司 | People's ER molecular chaperones of the secretion naturally recombinated are produced using people's ER molecular chaperones signal sequences native in yeast expression system |
-
2019
- 2019-10-08 GB GB201914516A patent/GB201914516D0/en not_active Ceased
-
2020
- 2020-10-07 JP JP2022521196A patent/JP2023500033A/en active Pending
- 2020-10-07 KR KR1020227015264A patent/KR20220079917A/en unknown
- 2020-10-07 WO PCT/EP2020/078173 patent/WO2021069523A1/en unknown
- 2020-10-07 EP EP20789562.4A patent/EP4041280A1/en active Pending
- 2020-10-07 US US17/767,232 patent/US20220370554A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4041280A1 (en) | 2022-08-17 |
WO2021069523A1 (en) | 2021-04-15 |
JP2023500033A (en) | 2023-01-04 |
US20220370554A1 (en) | 2022-11-24 |
KR20220079917A (en) | 2022-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3777830C0 (en) | Ophthalmic composition for treatment of dry eye disease | |
IL276383A (en) | Treatment of ophthalmologic diseases | |
IL281773A (en) | Ophthalmic composition for treatment of dry eye disease | |
IL287904A (en) | Combination treatment of arthritic disease | |
IL289405A (en) | Personalized treatment of ophthalmologic diseases | |
ZA202002075B (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
IL269698B (en) | Methods of preventing or treating ophthalmic diseases | |
SG11202001595SA (en) | Angio-3 for treatment of retinal angiogenic diseases | |
PL3886858T3 (en) | Compounds for treatment of eye diseases associated with excessive vascularisation | |
GB201914516D0 (en) | Treatment of eye disease | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
IL291626A (en) | Treatment of celiac disease | |
IL289221A (en) | Compounds for treatment of eye disorders | |
IL286099A (en) | Methods of treating disease with levoketoconazole | |
IL282361A (en) | Treatment of neurological diseases | |
GB201910645D0 (en) | Treatment for dry eye disease | |
GB201916506D0 (en) | Corneal tissue | |
GB201907305D0 (en) | Treatment of conditions | |
EP3658217A4 (en) | Treatment of eye disorders | |
GB201811911D0 (en) | Treatment of disease | |
GB201811912D0 (en) | Treatment of disease | |
GB201810974D0 (en) | Treatment of disease | |
GB201705435D0 (en) | Treatment of ocular disease | |
GB201904764D0 (en) | Treatment of ophthalmological conditions | |
GB201909438D0 (en) | Treatment of diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |